Apr 17, 2023 9:00am EDT Avalon GloboCare Announces Commercial Launch of KetoAir Breathalyzer at the KetoCon Austin 2023 Conference
Apr 11, 2023 9:00am EDT Avalon GloboCare Signs Agreement with Qi Diagnostics to Exclusively Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, U.K. and European Union
Feb 13, 2023 9:00am EST Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
Jan 17, 2023 9:00am EST Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Jan 11, 2023 9:00am EST Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
Jan 03, 2023 9:00am EST Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
Dec 14, 2022 9:00am EST Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
Dec 12, 2022 9:00am EST Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC